Show simple item record

dc.contributor.authorMedina Carbonero, Marta
dc.contributor.authorSanz Alcázar, Arabela
dc.contributor.authorBritti, Elena
dc.contributor.authorDelaspre, Fabien
dc.contributor.authorCabiscol Català, Elisa
dc.contributor.authorRos Salvador, Joaquim
dc.contributor.authorTamarit Sumalla, Jordi
dc.date.accessioned2022-03-25T08:05:53Z
dc.date.available2022-03-25T08:05:53Z
dc.date.issued2022
dc.identifier.issn1420-682X
dc.identifier.issn1420-9071
dc.identifier.urihttp://hdl.handle.net/10459.1/73417
dc.description.abstractFriedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene. The most prevalent mutation is a GAA expansion in the first intron of the gene causing decreased frataxin expression. Some patients present the GAA expansion in one allele and a missense mutation in the other allele. One of these mutations, FXNI154F, was reported to result in decreased content of mature frataxin and increased presence of an insoluble intermediate proteoform in cellular models. By introducing this mutation into the murine Fxn gene (I151F, equivalent to human I154F) we have now analyzed the consequences of this pathological point mutation in vivo. We have observed that FXNI151F homozygous mice present low frataxin levels in all tissues, with no evidence of insoluble proteoforms. Moreover, they display neurological deficits resembling those observed in FA patients. Biochemical analysis of heart, cerebrum and cerebellum have revealed decreased content of components from OXPHOS complexes I and II, decreased aconitase activity, and alterations in antioxidant defenses. These mitochondrial alterations are more marked in the nervous system than in heart, precede the appearance of neurological symptoms, and are similar to those observed in other FA models. We conclude that the primary pathological mechanism underlying the I151F mutation is frataxin deficiency, like in patients carrying GAA expansions. Therefore, patients carrying the I154F mutation would benefit from frataxin replacement therapies. Furthermore, our results also show that the FXNI151F mouse is an excellent tool for analyzing tissue-specific consequences of frataxin deficiency and for testing new therapies.ca_ES
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. FXNI151F Het mice were generated thanks to the BeHeard Challenge hosted by the Rare Genomics Institute (CA, USA). This work has also been funded by grants from Association Française de l´Ataxie de Friedreich – AFAF (obtained by FD) and from Ministerio de Economía y Empresa (MINECO, Spain, SAF2017-83883-R) (obtained by JR and JT).ca_ES
dc.language.isoengca_ES
dc.publisherSpringerca_ES
dc.publisherBirkhäuser Verlagca_ES
dc.relationMINECO/PN2013-2016/SAF2017-83883-Rca_ES
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1007/s00018-021-04100-5ca_ES
dc.relation.ispartofCellular and Molecular Life Sciences, 2022, vol. 79ca_ES
dc.rightscc-by (c)Authors, 2022ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectFriedreich Ataxiaca_ES
dc.subjectIron–sulfurca_ES
dc.subjectMitochondriaca_ES
dc.subjectOXPHOSca_ES
dc.subjectOxidative stressca_ES
dc.titleMice harboring the FXN I151F pathological point mutation present decreased frataxin levels, a Friedreich ataxia-like phenotype, and mitochondrial alterationsca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.identifier.idgrec032241
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1007/s00018-021-04100-5


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c)Authors, 2022
Except where otherwise noted, this item's license is described as cc-by (c)Authors, 2022